The global biosimilar monoclonal antibodies market was valued at US$ 1,516.9 Mn in 2016 and is projected to reach US$ 32,015.0 Mn in 2026 at a CAGR of 35.7% from 2017 to 2026. The Adalimumab drug class segment is estimated to account for the major revenue share of 29.1% by end of 2017, owing to its cost-effectiveness and capability to cure oncological diseases, Crohn’s colitis disease, and spondylitis.
Global Biosimilar Monoclonal Antibodies Market: Segmental Snapshot
By drug class: Adalimumab segment is estimated to register highest CAGR of over 37.7%, thereby accounting for highest revenue share among the drug class segments.
By application: Oncology segment is estimated to account for highest revenue share among the application segments, and register highest CAGR of over 38.0% over the forecast period.
By region: The market in Europe accounted for highest revenue share in the global biosimilar monoclonal antibodies market in 2016. Revenue from the market in Asia Pacific is expected to expand at a highest CAGR of over 36.9% over the forecast period.
Global Biosimilar Monoclonal Antibodies Market: Competitive Analysis
The research report on the global biosimilar monoclonal antibodies market includes major company profiles such as Pfizer Inc., Novartis AG, Reliance Life Sciences, Biocon, Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, BioXpress Therapeutics, SA., Coherus BioSciences, Inc., Genor BioPharma.
Embed This Image On Your Site (copy code below):